-
-
-
-
-
-
-
Leerink Partners Upgrades Agios Pharma (AGIO) to Outperform
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)
-
-
-
-
-
-
-
Agios' PYRUKYND approved for thalassemia treatment in Saudi Arabia
-
-
-
-
-
-
-
H.C. Wainwright Starts Agios Pharma (AGIO) at Buy
-
-
-
-
-
-
-
Agios Reports Business Highlights and Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
UPDATE: BofA Securities Starts Agios Pharma (AGIO) at Buy
-
-
-
-
-
-
-
Top 6 Healthcare Names To Buy On Weakness - Piper Jaffray
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

